Key Takeaways
- The Bank of England (BoE) maintained the Bank Rate at 3.75% in an 8-1 vote, while warning that inflation could peak at 6.2% by Q1 2027 under its most severe scenario.
- Eli Lilly (LLY) surged after reporting Q1 revenue of $19.80B, driven by massive demand for Mounjaro ($8.66B) and Zepbound ($4.16B), leading to a significant full-year guidance raise.
- Caterpillar (CAT) beat analyst estimates with $17.42B in revenue and adjusted EPS of $5.54, signaling continued strength in industrial demand and forecasting low double-digit growth for the year.
- Geopolitical tensions escalated as Iran’s Supreme Leader Khamenei claimed a "new chapter" for the Strait of Hormuz, vowing to dismantle U.S. influence in the region.
Bank of England Holds Steady Amid Inflationary Risks
The Bank of England opted to keep interest rates unchanged at 3.75% today, following an 8-1 vote by the Monetary Policy Committee. While Governor Andrew Bailey described the current rate as a "reasonable place," Chief Economist Huw Pill broke ranks to vote for a 25-basis-point increase, highlighting internal concerns over persistent price pressures.
The central bank significantly revised its inflation outlook, noting that CPI could average between 3.3% and 4.5% in 2026, well above previous projections of 2.2%. The BoE warned that it "stands ready" to act forcefully if "material" second-round effects from wage and price-setting emerge. Market participants are closely watching the BoE's shift in GDP forecasts, which were lowered to 0.7%-0.8% for 2026.
Pharmaceutical Giants Eli Lilly and Merck Report Strong Growth
Eli Lilly (LLY) delivered a powerhouse Q1 performance, reporting an adjusted EPS of $8.55, crushing the $6.66 estimate. The company’s weight-loss and diabetes portfolio continues to dominate, with Mounjaro and Zepbound combining for over $12.8B in quarterly sales. Consequently, Lilly raised its FY revenue guidance to a range of $82B to $85B.
Merck & Co (MRK) also beat top-line expectations with $16.29B in sales, supported by a 12% year-over-year increase in Keytruda revenue ($8.03B). Despite reporting an adjusted loss of $1.28 per share due to a one-time charge from the Cidara deal, the company raised its full-year adjusted EPS outlook to $5.04–$5.16. Bristol Myers Squibb (BMY) joined the trend, reporting $11.49B in revenue as Eliquis sales climbed 16% to $4.14B.
Industrials and Energy Show Resilience
Caterpillar (CAT) shares remain in focus after the company reported adjusted operating income of $3.13B, surpassing the $2.74B expected by analysts. The industrial giant sees Q2 sales and revenues trending higher than the previous year, despite potential headwinds from tariff costs. The report suggests that global infrastructure and construction demand remains robust despite tighter financial conditions.
In the energy sector, ConocoPhillips (COP) posted an adjusted EPS of $1.89, beating the $1.72 consensus, with total production reaching 2,309 MBOED. However, cash flow from operations came in light at $4.30B, missing the $5.06B estimate. Meanwhile, Valero Energy (VLO) reported a significant earnings beat with an adjusted EPS of $4.22 on revenues of $32.38B.
Geopolitical Uncertainty in the Middle East
The global energy market faces renewed uncertainty following comments from Iran's Supreme Leader Khamenei, who stated that Iran will guard its missile and nuclear technology "like its borders." Khamenei claimed that a "new chapter" is taking shape for the Gulf and the Strait of Hormuz, suggesting that the region would have a "bright future" without the presence of the United States.
Analysts remain concerned about the potential for supply disruptions in the Strait of Hormuz, a critical chokepoint for global oil transit. While some look to Venezuela's 300 billion barrels of reserves as a long-term solution, experts warn that the current supply gap requires immediate resolution that Venezuela cannot currently provide. Additional earnings notes included Cardinal Health (CAH) raising its outlook and L3Harris (LHX) increasing its GAAP EPS guidance for the full year.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.